Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Walaa E Kattan"'
Autor:
Sezer Acar, Huda A BinEssa, Korcan Demir, Roua A Al-Rijjal, Minjing Zou, Gönül Çatli, Ahmet Anık, Anwar F Al-Enezi, Seçil Özışık, Manar S A Al-Faham, Ayhan Abacı, Bumin Dündar, Walaa E Kattan, Maysoon Alsagob, Salih Kavukçu, Hamdi E Tamimi, Brian F Meyer, Ece Böber, Yufei Shi
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0193388 (2018)
Hereditary hypophosphatemia is a group of rare renal phosphate wasting disorders. The diagnosis is based on clinical, radiological, and biochemical features, and may require genetic testing to be confirmed.Clinical features and mutation spectrum were
Externí odkaz:
https://doaj.org/article/10b254c616884e3f832371affc2506e0
Autor:
Korcan Demir, Walaa E Kattan, Minjing Zou, Erdem Durmaz, Huda BinEssa, Özlem Nalbantoğlu, Roua A Al-Rijjal, Brian Meyer, Behzat Özkan, Yufei Shi
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0131376 (2015)
The CYP27B1 gene encodes 25-hydroxyvitamin D-1α-hydroxylase. Mutations of this gene cause vitamin D-dependent rickets type 1A (VDDR-IA, OMIM 264700), which is a rare autosomal recessive disorder. To investigate CYP27B1 mutations, we studied 8 patien
Externí odkaz:
https://doaj.org/article/e3903ac1b8b24c278d67482cbfa3e096
Autor:
Junchen Liu, Ransome van der Hoeven, Walaa E. Kattan, Jeffrey T. Chang, Dina Montufar-Solis, Wei Chen, Maurice Wong, Yong Zhou, Carlito B. Lebrilla, John F. Hancock
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
KRAS is a small GTPase that regulates cell proliferation. Here, the authors show that a subset of cell surface glycosphingolipids regulate KRAS plasma membrane localization by modulating inner leaflet lipid composition, uncovering a requirement for K
Externí odkaz:
https://doaj.org/article/7c042b78ee0049b58df0d81f70b376de
Autor:
Hema Adhikari, Walaa E. Kattan, Shivesh Kumar, Pei Zhou, John F. Hancock, Christopher M. Counter
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-21 (2021)
The lipid composition of the plasma membrane defines the localisation of KRAS and its oncogenic function. Here the authors show that EFR3A binds to active KRAS to recruit PI4KA and alters the lipid composition of the plasma membrane to promote KRAS o
Externí odkaz:
https://doaj.org/article/b15aa2d411704499ade6c2c0e8aff6f3
Autor:
Benjamin E. Mead, Conner Kummerlowe, Nuo Liu, Walaa E. Kattan, Thomas Cheng, Jaime H. Cheah, Christian K. Soule, Josh Peters, Kristen E. Lowder, Paul C. Blainey, William C. Hahn, Brian Cleary, Bryan Bryson, Peter S. Winter, Srivatsan Raghavan, Alex K. Shalek
Publikováno v:
bioRxiv
High-throughput phenotypic screens leveraging biochemical perturbations, high-content readouts, and complex multicellular models could advance therapeutic discovery yet remain constrained by limitations of scale. To address this, we establish a metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfd9ca0ca92084b2eca2635e8e0d40b7
https://europepmc.org/articles/PMC9900857/
https://europepmc.org/articles/PMC9900857/
Autor:
Christopher M. Counter, John F. Hancock, Hema Adhikari, Shivesh Kumar, Pei Zhou, Walaa E Kattan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-21 (2021)
The HRAS, NRAS, and KRAS genes are collectively mutated in a fifth of all human cancers. These mutations render RAS GTP-bound and active, constitutively binding effector proteins to promote signaling conducive to tumorigenic growth. To further elucid
Autor:
Walaa E. Kattan, Junchen Liu, Dina Montufar-Solis, Hong Liang, Bhargavi Brahmendra Barathi, Ransome van der Hoeven, Yong Zhou, John F. Hancock
Publikováno v:
Proc Natl Acad Sci U S A
KRAS is mutated in 90% of human pancreatic ductal adenocarcinomas (PDACs). To function, KRAS must localize to the plasma membrane (PM) via a C-terminal membrane anchor that specifically engages phosphatidylserine (PtdSer). This anchor-binding specifi
Autor:
Walaa E Kattan, John F. Hancock
Publikováno v:
Biochem J
The three human RAS proteins are mutated and constitutively activated in ∼20% of cancers leading to cell growth and proliferation. For the past three decades, many attempts have been made to inhibit these proteins with little success. Recently; how
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7a45971716bba7ed9d755b8b8d9f0d
https://europepmc.org/articles/PMC7891675/
https://europepmc.org/articles/PMC7891675/
Autor:
Afaf Alsagheir, Walaa E Kattan, Mohammad A. Alqahtani, Brian F. Meyer, Essa Y. Baitei, Minjing Zou, Ali S. Alzahrani, Anwar F Al-Enezi, Ali Al Qarni, Roua A. Al-Rijjal, Ali Al-Odaib, Omer Babiker, Yufei Shi, Manar S A Al-Faham, Huda A BinEssa
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 103:1889-1898
Context Congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, affecting one in 3000 to 4000 newborns. Since the introduction of a newborn screening program in 1988, more than 300 cases have been identified. The underlying gen
Autor:
Ransome van der Hoeven, Wei Chen, Tien Hung Lan, John F. Hancock, Walaa E Kattan, Xiaoping Ma, Dharini van der Hoeven
Publikováno v:
Life Science Alliance
KRAS-dependent cancer cell growth is inhibited by disrupting phosphatidylserine transport to the plasma membrane by genetic knockdown of lipid exchangers ORP5 and ORP8 or by inhibition of PI4KIIIα.
The small GTPase KRAS, which is frequently mut
The small GTPase KRAS, which is frequently mut